908 Devices Inc. (NASDAQ:MASS) Holdings Decreased by Sumitomo Mitsui Trust Holdings Inc.

Sumitomo Mitsui Trust Holdings Inc. lowered its position in 908 Devices Inc. (NASDAQ:MASS) by 7.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 582,034 shares of the company’s stock after selling 47,960 shares during the quarter. Sumitomo Mitsui Trust Holdings Inc. owned approximately 1.80% of 908 Devices worth $6,530,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of MASS. Global Retirement Partners LLC purchased a new position in 908 Devices in the third quarter valued at about $62,000. Values First Advisors Inc. grew its stake in 908 Devices by 24.5% in the third quarter. Values First Advisors Inc. now owns 16,726 shares of the company’s stock valued at $111,000 after purchasing an additional 3,294 shares in the last quarter. SG Americas Securities LLC purchased a new position in 908 Devices in the fourth quarter valued at about $133,000. Arete Wealth Advisors LLC grew its stake in 908 Devices by 35.8% in the third quarter. Arete Wealth Advisors LLC now owns 22,758 shares of the company’s stock valued at $152,000 after purchasing an additional 5,997 shares in the last quarter. Finally, New York State Common Retirement Fund grew its stake in 908 Devices by 15.3% in the third quarter. New York State Common Retirement Fund now owns 70,525 shares of the company’s stock valued at $470,000 after purchasing an additional 9,346 shares in the last quarter. Hedge funds and other institutional investors own 88.06% of the company’s stock.

Insiders Place Their Bets

In other 908 Devices news, CFO Joseph H. Iv Griffith sold 5,698 shares of the business’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $7.00, for a total value of $39,886.00. Following the completion of the sale, the chief financial officer now owns 89,711 shares of the company’s stock, valued at $627,977. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, CEO Kevin J. Knopp sold 9,071 shares of the business’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $7.00, for a total transaction of $63,497.00. Following the completion of the transaction, the chief executive officer now owns 411,981 shares of the company’s stock, valued at approximately $2,883,867. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Joseph H. Iv Griffith sold 5,698 shares of the business’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $7.00, for a total value of $39,886.00. Following the transaction, the chief financial officer now directly owns 89,711 shares of the company’s stock, valued at approximately $627,977. The disclosure for this sale can be found here. Insiders sold 20,001 shares of company stock valued at $139,955 over the last quarter. Insiders own 27.80% of the company’s stock.

908 Devices Price Performance

Shares of NASDAQ MASS opened at $5.56 on Wednesday. The business’s 50-day moving average price is $6.76 and its two-hundred day moving average price is $7.09. 908 Devices Inc. has a one year low of $4.85 and a one year high of $12.51. The company has a market capitalization of $182.98 million, a P/E ratio of -4.92 and a beta of 0.93.

908 Devices (NASDAQ:MASS) last announced its quarterly earnings results on Tuesday, March 5th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.03. 908 Devices had a negative return on equity of 21.09% and a negative net margin of 72.47%. The company had revenue of $14.40 million during the quarter, compared to analysts’ expectations of $14.16 million. During the same quarter in the previous year, the firm earned ($0.31) earnings per share. The business’s quarterly revenue was up 24.1% compared to the same quarter last year. On average, equities analysts anticipate that 908 Devices Inc. will post -1.27 EPS for the current year.

908 Devices Profile

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.